

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

**APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND
INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes:

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Ouyang Yunlong (“**Mr. Ouyang**”) has been appointed as a non-executive Director with effect from July 3, 2025.

The biographical details of Mr. Ouyang are set out as follows:

Mr. Ouyang, aged 38, demonstrates extensive experience in the financial industry and project management in the biomedical field. Since November 2017, Mr. Ouyang has been a partner at Shenzhen Sangel Capital Management Co., Ltd., where he focuses on venture capital investment in the biomedical industry and has a proven track record of raising and managing a series of RMB and USD venture capital funds.

From July 2010 to June 2015, Mr. Ouyang held the position of account manager and head of investment banking team at the Shenzhen Branch of the Industrial and Commercial Bank of China. From June 2015 to November 2017, he served as chairman of Shenzhen Xiaozi Intelligent Technology Co., Ltd.

Mr. Ouyang holds a Bachelor of Engineering degree from the Beijing Institute of Technology, which he obtained in June 2008. He subsequently completed a Master of Management degree at the same university in July 2010.

The Board considered and accepted the recommendation from the nomination committee of the Company (the “**Nomination Committee**”) to the appointment of Mr. Ouyang as a non-executive Director, after reviewing his work experience and professional qualifications.

Mr. Ouyang has entered into a service contract with the Company in relation to his appointment as a non-executive Director for a term of three years commencing from July 3, 2025, which may be terminated by not less than 3 months’ notice in writing served by either party on the other and is subject to termination provisions therein and provisions on retirement as set out in the articles of association of the Company. Pursuant to the Mr. Ouyang’s service contract, he is entitled to remuneration in accordance with the remuneration policies determined by the remuneration committee of the Board from time to time and, as at the date of this announcement, Mr. Ouyang is entitled to a director’s fee of US\$2,500 per regular quarterly meeting and, to the extent appropriate, any other ad hoc board meeting that requires significant contribution from the board members.

Save as disclosed above, as at the date of this announcement, Mr. Ouyang confirmed that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) he does not hold any other position with the Company or any members of the Group; (iii) he does not have any other major appointments and professional qualifications; (iv) he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; (v) he does not hold any interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other matter in relation to the appointment of Mr. Ouyang as a non-executive Director that needs to be brought to the attention of the shareholders of the Company and there is no other information relating to Mr. Ouyang which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Zhang Peng (“**Dr. Zhang**”) has been appointed as an independent non-executive Director with effect from July 3, 2025.

The biographical details of Dr. Zhang are set out as follows:

Dr. Zhang, aged 49, has approximately 21 years of experience in the therapeutic biologics industry. Dr. Zhang is a co-founder, an executive Director and a senior vice president of Akeso, Inc., a company listed in the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 9926).

Prior to the current positions, Dr. Zhang has served as a vice president of Akeso Biopharma Co., Ltd. since early 2012. He has been a director of AD Pharmaceuticals Co., Ltd. since February 2017, and a director of Akeso Pharma Co., Ltd. since November 2018. Dr. Zhang served as a teaching assistant in the Chemistry department of the University of Louisville in the U.S. from August 2001 to July 2002. From August 2002 to February 2007, he served as a teaching assistant in the Chemistry department of the University of Kentucky in the U.S. Dr. Zhang served as a scientist in PDL BioPharma, Inc. from February 2007 to May 2008 and then as a senior director of the protein chemical department of Crown Bioscience Inc. from September 2008 to April 2012. In addition, since June 2010, he also served as the senior director and deputy general manager of Taicang CrownBio Analytical and Testing Company Limited (中美冠科生物技術(太倉)有限公司), where he was primarily responsible for general management, business development and project management.

Dr. Zhang obtained his bachelor's degree in chemistry and master's degree in analytical chemistry from Shandong University (山東大學) in the PRC in July 1998 and June 2001, respectively. Dr. Zhang subsequently obtained his Ph.D. in chemistry from the University of Kentucky in the U.S. in May 2007. Dr. Zhang was selected as a member of the Pearl River Talents Scheme (珠江人才計劃) in April 2018 and recognized as a level 3 talent of the Shortage of High Level Talents of Zhongshan (中山市第三層次緊缺適用高層次人才) in February 2020. Dr. Zhang was awarded the Most Beautiful Constructor in Zhongshan 2022 (2022年度中山最美建設者) in March 2023, and the Guangdong Province May 1st Labor Medal (廣東省五一勞動獎章) in April 2023. Dr. Zhang was selected as one of the first directors of the Zhongshan New Social Class Federation (中山市新的社會階層人士聯合會) in July 2018.

The Board considered and accepted the recommendation from the Nomination Committee to the appointment of Dr. Zhang as an independent non-executive Director, after reviewing his education background, scientific credentials and professional experience.

Dr. Zhang has entered into a service contract with the Company in relation to his appointment as an independent non-executive Director for a term of three years commencing from July 3, 2025, which may be terminated by not less than 3 months' notice in writing served by either party on the other and is subject to termination provisions therein and provisions on retirement as set out in the articles of association of the Company. Pursuant to Dr. Zhang's service contract, he is entitled to remuneration in

accordance with the remuneration policies determined by the remuneration committee of the Board from time to time and, as at the date of this announcement, Dr. Zhang is entitled to a director's fee of HK\$360,000 per annum.

Save as disclosed above, as at the date of this announcement, Dr. Zhang confirmed that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) he does not hold any other position with the Company or any members of the Group; (iii) he does not have any other major appointments and professional qualifications; (iv) he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; (v) he does not hold any interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, Dr. Zhang has confirmed that (i) he has met the independence criteria as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interests in the business of the Company or its subsidiaries, and is not connected with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) he is not subject to any other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there is no other matter in relation to the appointment of Dr. Zhang as an independent non-executive Director that needs to be brought to the attention of the shareholders of the Company and there is no other information relating to Dr. Zhang which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Mr. Ouyang and Dr. Zhang to the Board.

By order of the Board

Sirnaomics Ltd.

Monin Ung

Chairlady and Independent Non-Executive Director

Hong Kong, July 3, 2025

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Mr. Ouyang Yunlong as non-executive Director, and Ms. Monin Ung, Dr. Cheung Hoi Yu, Mr. Wong Yu Shan Eugene and Dr. Zhang Peng as independent non-executive Directors.